Skip to main content

Table 3 Survival-related characteristics in advanced HG-SOCs who underwent NAC/IDS

From: Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer

Variable Univariate Multivariate
PFS OS PFS OS
FIGO stage
 IV 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 IIIc 3.03 (0.35–13.66) 4.24 (0.52–6.95) 2.28 (0.30–4.10) 3.57 (0.48–6.46)
Ascites
  > =500 ml 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
  < 500 ml 1.82 (1.45–2.85) 1.90 (1.56–2.98) 2.05 (1.40–2.95) 2.02 (1.66–4.08)
Outcome of surgery
 Suboptimal 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
 Optimal 1.52 (1.15–2.42) 1.66 (1.22–2.50) 1.93 (1.75–2.84) 2.20 (1.40–4.24)
Tumor sites
  > 3 1.00 (reference) 1.00 (reference) 1.00 (reference) 1.00 (reference)
  < = 3 1.32 (1.12–1.80) 1.49 (1.25–2.25) 1.26 (0.94–1.74) 1.40 (0.85–2.04)
Baseline CA-125 1.02 (1.01–1.08) 1.03 (1.01–1.08) 1.02 (0.97–1.07) 1.02 (0.98–1.06)
Preoperative CA-125 1.01 (1.00–1.04) 1.01 (1.00–1.04) 1.02 (0.96–1.05) 1.02 (0.96–1.05)
CA-125 decreasing kinetics 1.02 (1.00–1.04) 1.02 (1.00–1.04) 1.01 (1.00–1.04) 1.01 (1.00–1.05)